中华眼视光学与视觉科学杂志
中華眼視光學與視覺科學雜誌
중화안시광학여시각과학잡지
Chinese Journal of Optometry Ophthalmology and Visual Science
2015年
11期
685-689
,共5页
王月新%王黛%张阳阳%王君怡%贾艳妮%高华
王月新%王黛%張暘暘%王君怡%賈豔妮%高華
왕월신%왕대%장양양%왕군이%가염니%고화
角膜溃疡,真菌%角膜移植,穿透性%糖皮质激素%排斥%复发
角膜潰瘍,真菌%角膜移植,穿透性%糖皮質激素%排斥%複髮
각막궤양,진균%각막이식,천투성%당피질격소%배척%복발
Corneal ulcer,fungi%Keratoplasty,penetrating%Glucocorticoids%Rejection%Recurrence
目的 观察分析大直径穿透性角膜移植(LDPK)治疗严重真菌性角膜炎(FK)术后复发和免疫排斥反应发生的特点和规律,为提高手术后植片的长期存活提供参考.方法 回顾性病例研究.对2009年1月至2013年12月在青岛眼科医院行LDPK(植片直径大于9 mm)治疗严重FK的70例(70眼)患者进行随访,随访时间为6~48个月,观察感染的菌种类型及其分布情况、术后真菌复发和植片免疫排斥反应的特点和规律.对裸眼视力(UCVA)、最佳矫正视力(BCVA)和植片存活情况等进行随访.结果 70例患者发病至接受LDPK术的间隔时间为(23.7±11.7)d.真菌培养示首位菌种为镰刀菌属(72%).LDPK术后,8例(11%)患者真菌复发,平均复发时间为(6.8±2.9)d.65例(93%)患者保存了眼球.26例(37%)患者术后1个月内发生内皮型免疫排斥,平均排斥发生时间为(17.8±5.1)d,21例经抗排斥治疗后植片恢复透明;5例遗留局部或全角膜植片混浊.至最后一次随访,39例(56%)患者角膜植片透明,植片内皮细胞密度平均为(1 306±816)个/mm2,UCVA平均为4.0±3.8,BCVA平均为4.5±4.1.结论 LDPK术后真菌复发和免疫排斥反应的时间差存在规律,这个时间窗对在术后2周应用糖皮质激素预防免疫排斥反应和防止复发有积极意义.
目的 觀察分析大直徑穿透性角膜移植(LDPK)治療嚴重真菌性角膜炎(FK)術後複髮和免疫排斥反應髮生的特點和規律,為提高手術後植片的長期存活提供參攷.方法 迴顧性病例研究.對2009年1月至2013年12月在青島眼科醫院行LDPK(植片直徑大于9 mm)治療嚴重FK的70例(70眼)患者進行隨訪,隨訪時間為6~48箇月,觀察感染的菌種類型及其分佈情況、術後真菌複髮和植片免疫排斥反應的特點和規律.對裸眼視力(UCVA)、最佳矯正視力(BCVA)和植片存活情況等進行隨訪.結果 70例患者髮病至接受LDPK術的間隔時間為(23.7±11.7)d.真菌培養示首位菌種為鐮刀菌屬(72%).LDPK術後,8例(11%)患者真菌複髮,平均複髮時間為(6.8±2.9)d.65例(93%)患者保存瞭眼毬.26例(37%)患者術後1箇月內髮生內皮型免疫排斥,平均排斥髮生時間為(17.8±5.1)d,21例經抗排斥治療後植片恢複透明;5例遺留跼部或全角膜植片混濁.至最後一次隨訪,39例(56%)患者角膜植片透明,植片內皮細胞密度平均為(1 306±816)箇/mm2,UCVA平均為4.0±3.8,BCVA平均為4.5±4.1.結論 LDPK術後真菌複髮和免疫排斥反應的時間差存在規律,這箇時間窗對在術後2週應用糖皮質激素預防免疫排斥反應和防止複髮有積極意義.
목적 관찰분석대직경천투성각막이식(LDPK)치료엄중진균성각막염(FK)술후복발화면역배척반응발생적특점화규률,위제고수술후식편적장기존활제공삼고.방법 회고성병례연구.대2009년1월지2013년12월재청도안과의원행LDPK(식편직경대우9 mm)치료엄중FK적70례(70안)환자진행수방,수방시간위6~48개월,관찰감염적균충류형급기분포정황、술후진균복발화식편면역배척반응적특점화규률.대라안시력(UCVA)、최가교정시력(BCVA)화식편존활정황등진행수방.결과 70례환자발병지접수LDPK술적간격시간위(23.7±11.7)d.진균배양시수위균충위렴도균속(72%).LDPK술후,8례(11%)환자진균복발,평균복발시간위(6.8±2.9)d.65례(93%)환자보존료안구.26례(37%)환자술후1개월내발생내피형면역배척,평균배척발생시간위(17.8±5.1)d,21례경항배척치료후식편회복투명;5례유류국부혹전각막식편혼탁.지최후일차수방,39례(56%)환자각막식편투명,식편내피세포밀도평균위(1 306±816)개/mm2,UCVA평균위4.0±3.8,BCVA평균위4.5±4.1.결론 LDPK술후진균복발화면역배척반응적시간차존재규률,저개시간창대재술후2주응용당피질격소예방면역배척반응화방지복발유적겁의의.
Objective To observe the characteristics and regularity of recurrent and immune rejection after large-diameter penetrating keratoplasty (LDPK) for the treatment of severe fungal keratitis;to provide a reference for improving the postoperative long-term survival of corneal grafts.Methods In a retrospective case series study, 70 patients (70 eyes) with severe fungal keratitis who underwent LDPK (≥9.0 mm) at Qingdao Eye Hospital between January 2009 and December 2013 were included.The follow-up after surgery ranged from 6 to 48 months.The fungal strains were identified, the characteristics and frequency of recurrent and immune rejection episodes were monitored and the long-term survival of corneal grafts was evaluated.Uncorrected visual acuity and best corrected visual acuity were recorded.Results The average time of onset for all patients was 23.7±11.7 days.Fungal cultures showed that the main fungus was fusarium (72%).Postoperatively, 8 patients (11%) underwent recurrent fungal infection and the average recurrence time was 6.8±2.9 days.Sixty-five patients (93%) successfully maintained the structural integrity of the globe.The immunologic rejection occurred within one month after the surgery in 26 patients (37%) and the average rejection time was 17.8±5.1 days.Of these, 21 cases were treated in time, and the grafts became transparent after routine anti-rejection therapy, while the remaining grafts became partially or entirely opaque.Thirty-nine patients (56%) had a clear corneal graft at the last follow-up.Average endothelial cell density was 1 306±816/mm2, average UCVA was 4.0±3.8, and average BCVA was 4.5±4.1.Conclusion LDPK is an effective surgical method in the management of severe keratitis with a high success rate in restoring anatomical integrity and providing useful vision.Postoperatively, there is a regularity in the duration of time between fungal recurrence and immune rejection, which indicates the use of glucocorticoids within 2 weeks after surgery to prevent recurrent and immnune rejection episodes.